Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,791Revenue $M4,104Net Margin (%)15.5Altman Z-Score14.2
Enterprise Value $M37,108EPS $5.5Operating Margin %30.5Piotroski F-Score7
P/E(ttm)65.5Beneish M-Score-2.5Pre-tax Margin (%)29.9Higher ROA y-yY
Price/Book10.410-y EBITDA Growth Rate %--Quick Ratio3.3Cash flow > EarningsY
Price/Sales10.25-y EBITDA Growth Rate %--Current Ratio3.6Lower Leverage y-yY
Price/Free Cash Flow64.2y-y EBITDA Growth Rate %52.6ROA % (ttm)13.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)20.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M105ROIC % (ttm)23.7Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2016-03-31 Add0.71%$359.68 - $542.87
($414.39)
$ 360.64-13%Add 38.98%3,169,490
REGNKen Fisher 2016-03-31 Reduce$359.68 - $542.87
($414.39)
$ 360.64-13%Reduce -0.33%613
REGNVanguard Health Care Fund 2015-12-31 Reduce-0.17%$459.82 - $587.09
($543.11)
$ 360.64-34%Reduce -6.84%2,280,494
REGNJoel Greenblatt 2015-12-31 Buy 0.02%$459.82 - $587.09
($543.11)
$ 360.64-34%New holding4,157
REGNKen Fisher 2015-12-31 Add$459.82 - $587.09
($542.9)
$ 360.64-34%Add 22.02%615
REGNMario Gabelli 2015-12-31 Reduce$459.82 - $587.09
($543.11)
$ 360.64-34%Reduce -35.76%1,378
REGNVanguard Health Care Fund 2015-09-30 Reduce-0.32%$451.82 - $592.4
($537.03)
$ 360.64-33%Reduce -11.45%2,447,894
REGNRon Baron 2015-09-30 Reduce$451.82 - $592.4
($537.03)
$ 360.64-33%Reduce -0.21%7,463
REGNKen Fisher 2015-09-30 Reduce$451.82 - $592.4
($537.03)
$ 360.64-33%Reduce -10.80%504
REGNVanguard Health Care Fund 2015-06-30 Reduce-0.15%$438.27 - $539.4
($487.44)
$ 360.64-26%Reduce -5.36%2,764,540
REGNKen Fisher 2015-06-30 Add$438.27 - $539.4
($487.44)
$ 360.64-26%Add 5.81%565
REGNMario Gabelli 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 360.64-26%Reduce -2.05%2,145
REGNRon Baron 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 360.64-26%Reduce -0.15%7,479
REGNKen Fisher 2015-03-31 Add$396.89 - $488.87
($423.8)
$ 360.64-15%Add 1.91%534
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 360.64-8%Add 4.49%2,921,000
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 360.64-8%Sold Out0
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 360.648%Add 60.05%1,410
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 360.648%New holding583
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 360.6422%Add 60.34%2,795,500
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 360.6422%New holding2,295
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GOLDSTEIN JOSEPH LDirector 2016-04-06Sell2,000$425-15.14view
GOLDSTEIN JOSEPH LDirector 2016-03-21Sell2,000$375-3.83view
Sanofi10% Owner 2016-02-17Buy161,157$392.46-8.11view
Sanofi10% Owner 2016-01-12Buy83,938$465.04-22.45view
McCorkle Douglas SVP Controller and Asst Treasur 2015-12-29Sell3,954$552.08-34.68view
BROWN MICHAEL SDirector 2015-12-10Sell3,000$546.45-34view
YANCOPOULOS GEORGEPresident Regeneron Laboratori 2015-12-02Sell43,348$549.03-34.31view
VAGELOS P ROYChairman of the Board 2015-11-18Sell17,240$587.9-38.66view
SING GEORGE LDirector 2015-11-18Sell3,500$580-37.82view
Van Plew Daniel PSVP & General Mgr Industrial O 2015-11-10Sell5,123$554.85-35view

Quarterly/Annual Reports about REGN:

News about REGN:

Articles On GuruFocus.com
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals Nov 23 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Weekly CFO Sells Highlight: Acadia Healthcare, Facebook, Regeneron Pharmaceuticals Aug 24 2015 
Weekly Insider Sells Highlights: FB, AET, REGN, TYC Aug 18 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 

More From Other Websites
Regeneron beats revenue estimates, raises Eylea sales forecast May 05 2016
[$$] Regeneron Raises Sales Expectations for Eylea May 05 2016
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2016
Q1 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open May 05 2016
Regeneron beats 1Q profit forecasts May 05 2016
Regeneron beats 1Q profit forecasts May 05 2016
Regeneron first-quarter profit more than doubles May 05 2016
6:37 am Regeneron Pharma beats by $0.02, beats on revs May 05 2016
Regeneron Reports First Quarter 2016 Financial and Operating Results May 05 2016
IBB’s Large-Cap stocks: What Drove Regeneron’s Positive Results? May 03 2016
Big pharma dominates ranking of stocks with best 5-year returns May 03 2016
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More May 03 2016
How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take May 03 2016
Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018? May 03 2016
Regeneron (REGN) Q1 Earnings: Stock Likely to Disappoint May 02 2016
Regeneron Arthritis Pain Drug Scores In Mid-Stage Trial May 02 2016
Regeneron pain drug clears late-stage trial May 02 2016
Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with... May 02 2016
Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with... May 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)